IN2014DN06904A - - Google Patents
Info
- Publication number
- IN2014DN06904A IN2014DN06904A IN6904DEN2014A IN2014DN06904A IN 2014DN06904 A IN2014DN06904 A IN 2014DN06904A IN 6904DEN2014 A IN6904DEN2014 A IN 6904DEN2014A IN 2014DN06904 A IN2014DN06904 A IN 2014DN06904A
- Authority
- IN
- India
- Prior art keywords
- ang2
- ang2 binding
- binding molecules
- vhhs
- angiogenesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12162615 | 2012-03-30 | ||
PCT/EP2013/056635 WO2013144266A1 (en) | 2012-03-30 | 2013-03-27 | Ang2-binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06904A true IN2014DN06904A (es) | 2015-05-15 |
Family
ID=48190468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6904DEN2014 IN2014DN06904A (es) | 2012-03-30 | 2013-03-27 |
Country Status (27)
Country | Link |
---|---|
US (5) | US20130259859A1 (es) |
EP (1) | EP2831111B1 (es) |
JP (1) | JP5970734B2 (es) |
KR (1) | KR102020255B1 (es) |
CN (1) | CN104321344B (es) |
AU (1) | AU2013241769B2 (es) |
BR (1) | BR112014023415B1 (es) |
CA (1) | CA2865464C (es) |
CL (1) | CL2014002393A1 (es) |
CY (1) | CY1122007T1 (es) |
DK (1) | DK2831111T3 (es) |
EA (1) | EA031182B1 (es) |
ES (1) | ES2729165T3 (es) |
HR (1) | HRP20190817T1 (es) |
HU (1) | HUE044263T2 (es) |
IL (1) | IL234234B (es) |
IN (1) | IN2014DN06904A (es) |
LT (1) | LT2831111T (es) |
MX (1) | MX350248B (es) |
NZ (1) | NZ628584A (es) |
PH (1) | PH12014502179A1 (es) |
PL (1) | PL2831111T3 (es) |
PT (1) | PT2831111T (es) |
RS (1) | RS58732B1 (es) |
SI (1) | SI2831111T1 (es) |
TR (1) | TR201908638T4 (es) |
WO (1) | WO2013144266A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
EP3207059A1 (en) | 2014-10-17 | 2017-08-23 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
SG11201706840WA (en) * | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
BR112018001762A2 (pt) | 2015-07-29 | 2018-09-18 | Allergan Inc | anticorpos apenas de cadeia pesada para ang-2 |
US20190300967A1 (en) * | 2016-10-13 | 2019-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
KR102143132B1 (ko) * | 2016-12-26 | 2020-08-10 | 기초과학연구원 | 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물 |
CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
CN108659130B (zh) * | 2018-05-28 | 2021-09-10 | 长春力太生物技术有限公司 | 一种抗癌胚抗原纳米抗体及其应用 |
EP3813864A4 (en) | 2018-06-29 | 2022-07-20 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONISTS |
SG11202108832XA (en) * | 2019-02-25 | 2021-09-29 | Pharmabcine Inc | Anti-ang2 antibody and use thereof |
US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
WO2020263312A1 (en) | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
IL311318A (en) * | 2021-09-10 | 2024-05-01 | Soter Biopharma Pte Ltd | Anti-Ang2 antibody, its preparation method and its application |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69334305D1 (de) | 1992-08-21 | 2010-01-28 | Univ Bruxelles | Immunoglobuline ohne leichte Ketten |
US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
EP2267027A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
NZ563471A (en) | 2002-11-08 | 2009-04-30 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
US20080107601A1 (en) | 2004-10-13 | 2008-05-08 | Ablynx N.V. | Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease |
MX2007007484A (es) | 2004-12-21 | 2007-07-20 | Astrazeneca Ab | Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos. |
CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
RU2008152435A (ru) | 2006-06-06 | 2010-07-20 | Дженентек, Инк. (Us) | Композиции и способы регулирования развития сосудов |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
WO2008101985A2 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
EP3424526A1 (en) * | 2008-06-05 | 2019-01-09 | Ablynx NV | Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies |
CA2746395C (en) * | 2008-12-10 | 2019-07-09 | Ablynx N.V. | Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
-
2013
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja active Active
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en active Active
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en unknown
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt active IP Right Grant
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh active Active
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en active Application Filing
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active IP Right Grant
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
-
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179A1/en unknown
-
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
-
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
-
2019
- 2019-04-30 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
-
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06904A (es) | ||
TN2013000390A1 (en) | Bispecific binding molecules binding to vegf and ang2 | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2013002379A (es) | Moleculas de union a vegf. | |
TN2012000144A1 (en) | Dll4-binding molecules | |
TN2012000145A1 (en) | Bispecific binding molecules for anti-angiogenesis therapy | |
MX2012011771A (es) | Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf. | |
WO2015109124A3 (en) | Immunomodulatory agents | |
WO2014004549A3 (en) | Anti-mesothelin binding proteins | |
TN2013000389A1 (en) | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 | |
HUE054115T2 (hu) | Új antigénkötõ fehérjék és rák kezelésére történõ alkalmazásuk címzõtermékként | |
IN2014DN05756A (es) | ||
EA201591898A1 (ru) | Антитела, направленные на m-csf |